Journal Mobile Options
Table of Contents
Vol. 86, No. 2, 2011
Issue release date: March 2011
Urol Int 2011;86:161–166
(DOI:10.1159/000322964)

Prostate Cancer Does Not Influence Androgen Levels: A Radical Prostatectomy Cohort Study

De Nunzio C. · Carluccini A. · Cicione A. · Squillacciotti S. · Trucchi A. · Cantiani A. · Leonardo C. · Tubaro A.
Department of Urology, Ospedale Sant’Andrea, University ‘La Sapienza’, Rome, Italy

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Aim: To investigate the relationship between androgens and prostate cancer in patients scheduled for radical prostatectomy. Subjects and Methods: Patients scheduled for open radical prostatectomy were enrolled. Blood samples were collected before prostate biopsy and 12 months later to evaluate testosterone, free testosterone, sex hormone-binding globulin (SHBG), PSA, calculated free and bioavailable testosterone. Results: 44 patients were consecutively enrolled. 15 patients (34%) presented a Gleason score (GS) of 6, 24 patients GS 7 (54%), 1 patient (2%) GS 8, and 4 patients GS 9 (9%). Mean prostate cancer volume was 4.3 ± 5.7 cm3. 24 patients presented a pT2 stage, 16 a pT3a stage, and 4 a pT3b stage. Positive surgical margins were detected in 12 patients (27.3%). No significant change of testosterone (4.21 ± 1.49 vs. 4.00 ± 1.48 ng/ml, p = 0.46), free testosterone (9.01 ± 3.64 vs. 8.85 ± 3.04 pg/ml, p = 0.83), SHBG (38 ± 14.39 vs. 38.5 ± 17.23 nmol/l, p = 0.71), calculated free testosterone (0.091 ± 0.13 vs. 0.067 ± 0.026, p = 0.563), and bioavailable testosterone (1.89 ± 0.722 vs. 1.88 ± 0.53, p = 0.912) was observed. Conclusions: In our single-center study, prostate cancer does not impact on serum androgen levels, however our results should be confirmed in a larger study.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen YC, Stampfer MJ, Willett WC, Giovannucci E: Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 2005;14:1262–1269.
  2. Severi G, Morris HA, MacInnis RJ, English DR, Tilley WD, Hopper JL, Boyle P, Giles GG: Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:86–91.
  3. Wiren S, Stocks T, Rinaldi S, Hallmans G, Bergh A, Stenman U, Kaaks R, Stattin P: Androgens and prostate cancer risk: a prospective study. Prostate 2007;67:1230–1237.
  4. Morgentaler A: Testosterone and prostate cancer: a historical perspective on a modern myth. Eur Urol 2006;50:935–939.
  5. De Nunzio C, Miano R, Trucchi A, Finazzi Agrò E, Tubaro A: Finasteride for prostatic disease: an updated and comprehensive review. Expert Opin Drug Metab Toxicol 2008;4:1561–1568.
  6. Huggins C, Hodge GB: Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293–297.
  7. McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E: Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992;74:505–508.
  8. Olsson M, Ekstrom L, Schulze J, Kjellman A, Akre O, Rane A, Gustafsson O: Radical prostatectomy: influence on serum and urinary androgen levels. Prostate 2010;70:200–205.
  9. Hsing AW, Sakoda LC, Streamson CC: Obesity, metabolic syndrome and prostate cancer. Am J Clin Nutr 2007;86:843–857.
  10. Miller LR, Partin AW, Chan DW, Bruzek DWC, Dobs AS, Epstein JI, Walsh PC: Influence of radical prostatectomy on serum hormone levels. J Urology 1998;160:449–453.
  11. Lackner J, Maerk I, Koller A, Bieglmayer C, Marberger M, Kratzik C, Schatzl G: Serum inhibin – not a cause of low testosterone levels in hypogonadal prostate cancer? Urology 2008;72:1121–1124.
  12. De Nunzio C, Trucchi A, Miano R, Stoppacciaro A, Fattahi H, Cicione A, Tubaro A: The number of positive cores for high-grade prostatic intraepithelial neoplasia on initial biopsy is associated with prostate cancer on second biopsy. J Urol 2009;181:1069–1074.
  13. Epstein JI, Helpap B, Algaba F, Humphrey PA, Allsbrook WC, Iczkowski KA: Acinar adenocarcinoma; in Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds): WHO Classification of Tumors: Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs. Lyon, IARC Press, 2004, pp 162–192.
  14. Vermeulen A, Verdonck L, Kaufman JM: A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666–3672.
  15. Buschemeyer WC, Freedland SJ: Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol 2007;52:331–343.
  16. Schatzl G, Madersbacher S, Thurridl T, Waldmuller J, Kramer G, Haitel A, Marberger M: High-grade prostate cancer is associated with low serum testosterone levels. Prostate 2001;47:52–58.
  17. Hoffman MA, DeWolf WC, Morgentaler A: Is low serum free testosterone a marker for high-grade prostate cancer? J Urol 2000;163:824–827.
  18. Madersbacher S, Schatzl G, Bieglmayer C, Reiter WJ, Gassner C, Berger P, Zidek T, Marberger M: Impact of radical prostatectomy and TURP on the hypothalamic pituitary gonadal hormone axis. Urology 2002;60:869–874.
  19. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr: The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215–224.
  20. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS: Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192–1120.
  21. Salonia A, Briganti A, Gallina A, Karakiewicz P, Shariat S, Freschi M, Zanni G, Capitanio U, Bosi E, Rigatti P, Montorsi F: Sex hormone-binding globulin: a novel marker for nodal metastases prediction in prostate cancer patients undergoing extended pelvic lymph node dissection. Urology 2009;73:850–855.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50